Introduction
============

Prostate cancer (PCa) is the sixth most common cancer worldwide and the most prevalent cancer in men [@bib1] with a lifetime risk of 16.48% [@bib2]. Older age is an important PCa risk factor, as about three-quarters of all cases occur in men over 65 years [@bib3]. Age dependence in cancers could be the result of accumulation of DNA damage [@bib4] or epigenetic changes [@bib5] in somatic cells. Imprinting is one mechanism of epigenetic gene regulation. Imprinted genes carry epigenetic marks (e.g. methylation) that usually allow expression of only one allele in a parent-of-origin-dependent fashion [@bib6]. Loss of imprinting (LOI) is considered one of the earliest [@bib7] and most abundant alterations in cancer [@bib8]. Among the 90 imprinted genes known to date, the insulin-like growth factor 2 (*IGF2*) and *H19*, a gene for a noncoding RNA, are probably studied best [@bib9]. *IGF2* is of special interest, as it belongs to a small set of imprinted genes that can be studied in peripheral blood, shows monoallelic expression in normal blood lymphocytes, and has been linked to tumorigenesis [@bib10]. As epigenetic changes such as LOI and demethylation occur early in cancer progression, detection of such changes may be relevant for early cancer detection and prevention. LOI of *IGF2* has previously been described in normal circulating peripheral blood lymphocytes of individuals with an increased risk to develop colorectal cancer [@bib11].

*IGF2* and *H19* belong to the same locus and share similar expression patterns throughout most normal tissues. Imprinting of the *IGF2/H19* locus involves a so-called differentially methylated region (DMR) that acts as a boundary or insulator element. On the maternally inherited allele, the DMR is unmethylated allowing binding of the zinc finger protein CTCF to seven so-called imprinting control regions (ICRs) within the DMR, thereby preventing downstream enhancer elements from activating *IGF2*. On the paternally inherited allele, CTCF binding to the ICRs is blocked through methylation, allowing the downstream enhancers to interact with the *IGF2* promoter and expression of *IGF2* [@bib14] ([Fig. 1](#fig1){ref-type="fig"}). Using chromatin conformation capture, it was shown that these steps involve chromosomal looping and are accompanied by spatial translocation of the gene locus within the nucleus [@bib16].

IGFs regulate cell growth and differentiation in humans. IGF2 is the predominant IGF in adults [@bib17] and is imprinted in most tissues with few exceptions such as choroid plexus, leptomeninges, developing retina, and thymus [@bib18]. LOI and increased expression of *IGF2* are observed in many cancers [@bib20] including PCa [@bib21]. Among other effects, biallelic IGF2 supply has been shown to enhance the effect of PTEN loss in transgenic animals [@bib23].

To investigate whether LOI of *IGF2* was related also to the risk to develop PCa, we analyzed normal peripheral blood mononuclear cells (PBMNCs) from 113 male patients with a history of radical prostatectomy (RPE) for histologically proven PCa who were PSA negative at the time the blood sample was collected. Data were compared with blood samples from 246 PSA-negative healthy blood donors.

Materials and methods
=====================

Patient and control blood samples
---------------------------------

Peripheral blood samples from 113 prostatectomized patients with histologically proven PCa (RPE patients) were collected 12--36 months after RPE (age range 47--85 years, median 67 years). Only persons with PSA levels ≤0.2 and without clinical evidence of disease at follow-up were included. As controls, we used 246 blood samples from volunteer blood donors (age range 19--82 years, median 43 years). Samples were not tested for PSA levels. Informed written consent was obtained from all tested individuals after full explanation of the purpose and nature of all procedures used. The study was approved by the Local Ethics Committee (ref no. Wü 59/04), functioning according to the 3rd edition of the Guidelines on the Practice of Ethical Committees in Medical Research issued by the Royal College of Physicians of London.

Isolation of serum and nucleic acids from peripheral blood samples
------------------------------------------------------------------

Blood samples were processed within 1 h. Serum and PBMNCs were obtained after Ficoll--Hypaque density-gradient centrifugation as described [@bib24]. DNA and RNA were isolated from PBMNCs using the QIAamp kit (Qiagen) and the peqGold Blood RNA Kit (PeqLab, Erlangen, Germany) according to the manufacturer\'s instructions.

ELISA
-----

ELISA assays to detect serum IGF2 and IGFBP3 were purchased from Diagnostic System Laboratories (Webster, TX, USA) and performed according to the manufacturer\'s instructions. All serum samples were assayed in triplicates. The mean of the three values was used for further statistical evaluation.

Single nucleotide polymorphism genotyping by restriction-fragment length polymorphism
-------------------------------------------------------------------------------------

Heterozygosity at the ApaI-sensitive 820G\>A locus on exon 7 of the *IGF2* gene (GenBank sequence: [X07868](http://www.ncbi.nlm.nih.gov/gene?term=X07868)) was determined as described previously [@bib25]. In brief, DNA was amplified using primers F: 5′-CTTGGACTTTGAGTCAAATTGG-3′ and R: 5′-GGTCGTGCCAATTACATTTCA-3′, followed by HinfI and ApaI digestion.

Analysis for LOI of IGF2
------------------------

LOI or retention of imprinting (ROI) was determined by cDNA amplification from heterozygous cases by a nested RT-PCR method. In brief, total RNA was treated with DNAseI before RT. cDNA (1 μl) was amplified by 40 cycles of PCR using F: 5′-TCCTGGAGACGTACTGTGCTA-3′ and R: 5′-CGGGGATGCATAAAGTATGAG-3′ as primers. One microliter of the amplification product was used as a template for another 40 cycles using primers F: 5′-ACCGTGCTTCCGGACAAC-3′ (exon spanning) and R: 5′-GGTCGTGCCAATTACATTTCA-3′. The obtained PCR products were ethanol precipitated before direct DNA bidirectional sequencing using an ABI BigDye Terminator V1.1 cycle sequencing kit (Applied Biosystems, Inc., Foster City, CA, USA) and analyzed on a Genetic Analyzer 3110 (Applied Biosystems). The sequencing results were analyzed with CHROMAS Software version 2.0 (Technelysium Pty Ltd., South Brisbane, Australia). LOI was calculated as the ratio of the less active allele/more active allele, with LOI defined as an LOI index \>0.25. With this definition, the mean LOI index of cases with intact imprinting was 0.16±0.05 and was not different between controls and RPE patients. The mean LOI index of cases with LOI was 0.55±0.22 and was also not different between controls and RPE patients (*P*=0.06).

Bisulfite treatment
-------------------

DNA methylation analyses, starting with 1--2 μg DNA, were carried out using bisulfite treatment and subsequent sequencing as described previously [@bib26]. For PCR amplification of bisulfite-treated DNA, primers specific for methylated and unmethylated sequences spanning the seven CpG-rich *IGF2* ICRs located 2 kb upstream of the *H19* transcription site were designed after published sequences (GenBank ID: [283120](http://www.ncbi.nlm.nih.gov/gene?term=283120); primers available upon request). The obtained PCR products were sequenced and the results were analyzed using CHROMAS Software version 2.0. The relative percentage of methylated vs unmethylated bases at a given CG site was calculated by dividing the amplitudes for C\'s (i.e. methylated bases) by the amplitudes for T\'s (i.e. unmethylated bases).

Statistical analyses
--------------------

The allelic frequencies were compared with *χ* ^2^-test calculated on 2×2 contingency tables. The odds ratio (OR) was calculated to demonstrate the strength of difference between groups of subjects. *χ* ^2^-Test was also used to test for deviation from Hardy--Weinberg equilibrium. Mann--Whitney *U* test was used for statistical comparisons between unrelated groups. Spearman\'s test was used to test for correlations between variables. A *P* value \<0.05 was considered statistically significant.

Results
=======

Biased distribution of 820G/A alleles in prostate carcinoma patients
--------------------------------------------------------------------

The distribution of the 820G/A genotypes in RPE patients and control persons is summarized in [Table 1](#tbl1){ref-type="table"}. Among men with a history of PCa, the 820G/A genotype was significantly more frequent than among healthy control persons (50.5% in RPE patients vs 43% in controls; OR 1.92, 95% confidence interval 1.22--3.02, *P*=0.005), resulting in a deviation from expected Hardy--Weinberg proportions (*P*=0.001). Of note, among RPE patients, men with 820G/A were significantly younger (median age at diagnosis 65 years, range 49--83) at PCa diagnosis than men with the G/G (median age at diagnosis 69 years, range 47--85) or the A/A genotype (median age at diagnosis 73 years, range 65--85) (*P*\<0.0001; [Fig. 2](#fig2){ref-type="fig"}). 820G/A was previously found to be associated with body mass index (BMI) [@bib27]. To test whether the observed age difference were linked to differences in body weight, we compared BMI of 820G/A patients to those with other genotypes but found no statistical difference (*P*=0.17, data not shown).

LOI and increased IGF2 levels in the serum of PSA-negative RPE patients
-----------------------------------------------------------------------

cDNA from 106 informative cases (41 RPE patients and 65 controls with 820G/A genotype) was tested for LOI status. In control persons, IGF2 levels were tightly correlated with *IGF2* imprinting status (*r*=0.6, *P*\<0.05). LOI was present in 13/65 (20%) of the samples and was associated with a 35% increase in IGF2 levels in the serum (IGF2 in control persons with ROI 993±172.8 ng/ml vs LOI 1302±107.5 ng/ml, *P*=0.001; [Fig. 3](#fig3){ref-type="fig"}). The percentage of cases with LOI in control persons was identical for all age groups and did not increase with age.

LOI in RPE patients was significantly more frequent (16/41 cases (39%), *P*=0.03). In contrast to controls, IGF2 levels in all RPE patients were significantly increased and appeared uncoupled from the imprinting status (IGF2 levels in patients with ROI 1377±333.6 ng/ml vs LOI 1310±126.1 ng/ml, *P*=0.9; [Fig. 3](#fig3){ref-type="fig"}). Interestingly, circulating IGF2 levels in LOI cases in controls and ROI/LOI in RPE patients were similar, suggesting that under normal conditions, ∼35% of circulating IGF2 in the serum is regulated by imprinting. ELISA testing showed that IGF2 protein levels both in patients and in controls were tightly correlated with IGFBP3 levels (*r*=0.8, *P*\<0.0001; data not shown), indicating that the vast majority of the detected IGF2 was bound to IGFBP3.

Hypermethylation of IGF2 ICRs in blood cells of RPE patients
------------------------------------------------------------

To further investigate the reasons for the observed uncoupling of *IGF2* levels from imprinting status in RPE patients, we analyzed methylation of the ICRs 1--7 ([Fig. 4](#fig4){ref-type="fig"}). Hypermethylation in one or several of these regions is thought to interfere with CTCF binding, to favor loss of *IGF2* imprinting and hence to increase *IGF2* expression. In general agreement with the CTCF boundary model, we observed a higher degree of methylation in samples with LOI than in ROI in both RPE patients (LOI vs ROI, 36--100% methylation; mean, 80.9 vs 28--100% methylation; mean value, 68.7%) and controls (LOI vs ROI, 27--91% methylation; mean, 62.7 vs 27--82% methylation; mean, 53.7%). However, all ICRs in samples of RPE patients, irrespective of the imprinting status, showed a higher degree of methylation compared with control samples (percent methylated bases RPE vs controls (ROI samples), ICR1 63 vs 60%; ICR2 75 vs 58%; ICR3 100 vs 82%; ICR4 78 vs 33%; ICR5 73 vs 64%; ICR6 64 vs 52%; and ICR7 28 vs 27%). We hypothesize that IGF2 imprinting in peripheral blood cells of RPE patients may be incomplete due to global ICR hypermethylation.

Discussion
==========

It has previously been reported that LOI for *IGF2* is an epigenetic marker of colorectal cancer risk [@bib12]. In a similar approach, we studied IGF2 and its regulation in the peripheral blood of patients with a history of PCa who where PSA negative at the time when the blood sample was collected. It is a commonly held view that increased circulating IGF2 is a tumor product [@bib28]. We here show that this traditional view may be inaccurate for PCa patients: our findings in non-neoplastic blood cells rather point to a general relaxation of *IGF2* imprinting in these patients. We found enrichment of the 820G/A genotype among patients with a history of PCa (OR 1.92, *P*=0.005), a finding that may merit further consideration in future population studies. However, this retrospective study was not intended nor statistically powered to detect risk alleles in a general population. Thus, the more important finding was the fact that 820G/A genotype was a risk factor among RPE patients, as men with 820G/A were on average 5 years younger at PCa diagnosis than patients with a *G/G* or *A/A* genotype. The reasons for this observation are unclear. 820G/A was previously found to be associated with BMI [@bib27]. Currently available data suggest a possible correlation between obesity and PCa risk [@bib31]. However, we found no correlation between 820G/A alleles and BMI (data not shown). *IGF2* lies in a 19 kb genomic PCa risk region on chromosome 11p15.5, together with insulin (INS) and tyrosine hydroxylase (TH) [@bib34]. Many of the single nucleotide polymorphisms (SNPs) in this region are in tight linkage disequilibrium with each other. In line with previous reports, we did not observe co-segregation of 820G/A with other published risk alleles (+1127 *INS*-PstI and −4217 *TH*-PstI) [@bib35] (data not shown). This strongly suggests that 820G/A is a putative risk allele of its own.

Using the 820G/A SNP to study imprinting of IGF2, we found that 20% of healthy male control persons showed LOI. In line with previous observations [@bib11], the percentage of LOI cases was identical in all age groups, suggesting that LOI in peripheral blood cells is a genetically imposed condition rather than an age-related phenomenon. Cui *et al*. [@bib12] found LOI in peripheral blood lymphocytes to be predictive of LOI in both normal and cancerous colonic mucosa of patients with colorectal cancer. Interestingly, Fu *et al*. [@bib22] reported a more pronounced relaxation of imprinting in prostates of men with PCa than in age-matched control patients without PCa. These previous observations together with the data presented here raise the possibility that LOI in peripheral blood cells reflects a general impairment of imprinting rather than a tissue-restricted pre-neoplastic process. LOI in control persons resulted in a 35% increase in circulating IGF2. In stark contrast to control persons, in whom imprinting status and *IGF2* expression level were tightly correlated, *IGF2* imprinting and expression were uncoupled in RPE patients and IGF2 protein levels were also increased (again by 35%) in patients with ROI. These results indicate that ∼35% of circulating IGF2 is controlled by imprinting. One possible explanation for the increased serum IGF2 came from the observation that the ICRs 1--7 in peripheral blood cells of RPE patients were moderately hypermethylated, suggesting impaired CTCF binding and consequent incomplete or 'leaky' imprinting. Discordance between methylation and imprinting status at the *IGF2/H19* locus has been previously observed [@bib36] pointing to epigenetic mechanisms other than DNA methylation [@bib10]. Importantly, increased IGF2 protein levels in spite of apparently retained imprinting at the *IGF2/H19* locus were observed not only in virtually 100% RPE patients with ROI but also in a few control persons. As the controls of this study were persons who were anonymized blood donor volunteers that had not been interviewed for a history of prostatic disease nor tested for PSA levels, this raises the possibility that those few control persons with uncoupling of IGF2 from imprinting may have had occult PCa.

In conclusion, our results suggest that assessment of the *IGF2 820G/A* locus may provide clinically relevant information with respect to PCa risk and age of onset. Uncoupling of IGF2 imprinting from IGF2 levels and hypermethylation of the ICR in circulating peripheral blood lymphocytes may indicate persons at risk warranting increased surveillance. It will be important to test this prediction in a longitudinal prospective cohort in persons at risk to develop PCa and eventually also other cancers.

Author contribution statement
=============================

D Belharazem, M Kirchner, F Geissler, P Bugert, C Sauer, B Kneitz, and S Küffer performed experiments and assisted in the preparation of the manuscript. P Bugert, M Spahn, H Riedmiller, L Trojan, C Bolenz, and M S Michel were in charge of patients, collected patient and control samples, and participated in writing of the manuscript. A Marx and P Ströbel were principal investigators who designed and supervised the study and were involved in writing and editing the manuscript.

Declaration of interest
=======================

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
=======

This work was supported by the Interdisciplinary Center for Clinical Research (IZKF) of the University of Würzburg and by grant STR-638/2-1 of the Deutsche Forschungsgemeinschaft (DFG). The authors gratefully acknowledge expert help with statistical methods by Dr Klaus Jung, Department of Medical Statistics, University Medical Center Göttingen, Germany.

###### 

820G/A (ApaI) genotype frequencies and Hardy--Weinberg (HW) equilibrium test in peripheral blood mononuclear cells (PBMNCs) in the blood of patients with a history of radical prostatectomy (RPE) for prostate cancer.

                   ***n***   **G/G**       **A/G**      **A/A**     ***P* value for HW**
  ---------------- --------- ------------- ------------ ----------- ----------------------
  PBMNC RPE        113       40 (43%)      67 (50.5%)   6 (6.5%)    0.001
  PBMNC controls   246       119 (48.5%)   106 (43%)    21 (8.5%)   0.702

The allelic frequencies between RPE patients and controls were statistically different (*P*=0.02).

![Schematic representation of the *IGF2/H19* locus. According to the CTCF boundary model, CTCF binds to unmethylated motifs within the seven imprinting control regions (ICRs) on the maternal allele and prevents activation of *IGF2* through blockade of enhancer elements (E). On the paternal allele, the ICRs are methylated, thereby preventing CTCF binding and leading to activation of *IGF2* through the enhancer.](ec-01-87-g001){#fig1}

![Correlation between IGF2 820G/A allele status and age at tumor diagnosis in patients with a history of prostate cancer. Patients with an 820G/A genotype were on average 4 years younger than patients with an 820G/G genotype and 8 years younger than patients with an 820A/A genotype.](ec-01-87-g002){#fig2}

![Circulating IGF2 protein levels in patients with a history of prostate cancer (RPE patients) and control persons. In controls, IGF2 levels were significantly higher in persons with loss of imprinting (LOI) compared with persons with ROI with an average increase of 35% in persons with LOI (\*\**P*=0.001). In RPE patients, in contrast, there was no difference between cases with and without LOI (NS, not significant).](ec-01-87-g003){#fig3}

![Comparison of imprinting status of the imprinting control regions (ICR) 1--7 within the *IGF2/H19* locus in six patients with a history of prostate cancer (RPE) and six controls (schematic representation of results: black circles, methylated; gray circles, unmethylated CGs). In both groups, three cases (nos 1--3) with either loss (LOI) or retention (ROI) of *IGF2* imprinting were analyzed. In controls with LOI, all ICRs were hypermethylated compared to cases with ROI. In RPE patients, ICRs showed a higher degree of methylation. Note complete methylation of CGs within ICR3.](ec-01-87-g004){#fig4}
